TEVA PHARMACEUTICAL INDUSTRIES LTD Quarterly Operating Income (Loss) in USD from Q1 2010 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Teva Pharmaceutical Industries Ltd quarterly/annual Operating Income (Loss) history and growth rate from Q1 2010 to Q2 2024.
  • Teva Pharmaceutical Industries Ltd Operating Income (Loss) for the quarter ending June 30, 2024 was -$5M, a 99.2% increase year-over-year.
  • Teva Pharmaceutical Industries Ltd Operating Income (Loss) for the twelve months ending June 30, 2024 was $877M.
  • Teva Pharmaceutical Industries Ltd annual Operating Income (Loss) for 2023 was $433M.
  • Teva Pharmaceutical Industries Ltd annual Operating Income (Loss) for 2022 was -$2.2B, a 228% decline from 2021.
  • Teva Pharmaceutical Industries Ltd annual Operating Income (Loss) for 2021 was $1.72B.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $877M -$5M +$649M +99.2% Apr 1, 2024 Jun 30, 2024 10-Q 2024-07-31
Q1 2024 $228M -$218M -$205M -1577% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-08
Q4 2023 $433M $756M +$1.7B Oct 1, 2023 Dec 31, 2023 10-K 2024-02-12
Q3 2023 -$1.26B $344M -$80M -18.9% Jul 1, 2023 Sep 30, 2023 10-K 2024-02-12
Q2 2023 -$1.18B -$654M +$313M +32.4% Apr 1, 2023 Jun 30, 2023 10-Q 2024-07-31
Q1 2023 -$1.5B -$13M +$700M +98.2% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 -$2.2B -$940M -$1.02B -1321% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-12
Q3 2022 -$1.18B $424M -$199M -31.9% Jul 1, 2022 Sep 30, 2022 10-K 2024-02-12
Q2 2022 -$980M -$967M -$1.55B -266% Apr 1, 2022 Jun 30, 2022 10-K 2024-02-12
Q1 2022 $569M -$713M -$1.15B -264% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-10
Q4 2021 $1.72B $77M -$329M -81% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-12
Q3 2021 $2.05B $623M +$4.97B Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 -$2.92B $582M +$409M +236% Apr 1, 2021 Jun 30, 2021 10-Q 2022-07-27
Q1 2021 -$3.33B $434M +$243M +127% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-03
Q4 2020 -$3.57B $406M +$258M +174% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-10
Q3 2020 -$3.83B -$4.34B -$4.26B -5260% Jul 1, 2020 Sep 30, 2020 10-Q 2021-10-27
Q2 2020 $431M $173M +$817M Apr 1, 2020 Jun 30, 2020 10-Q 2021-07-28
Q1 2020 -$386M $191M +$57M +42.5% Jan 1, 2020 Mar 31, 2020 10-Q 2021-04-28
Q4 2019 -$443M $148M +$3.31B Oct 1, 2019 Dec 31, 2019 10-K 2022-02-09
Q3 2019 -$3.76B -$81M -$97M -606% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 -$3.66B -$644M -$630M -4500% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-05
Q1 2019 -$3.03B $134M -$1.39B -91.2% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 -$1.64B -$3.16B +$9.85B +75.7% Oct 1, 2018 Dec 31, 2018 10-K 2021-02-10
Q3 2018 -$11.5B $16M -$362M -95.8% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-07
Q2 2018 -$11.1B -$14M +$5.73B +99.8% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-07
Q1 2018 -$16.9B $1.53B +$630M +70.4% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-02
Q4 2017 -$17.5B -$13B -$12.9B -9401% Oct 1, 2017 Dec 31, 2017 10-K 2020-02-21
Q3 2017 -$4.6B $378M -$387M -50.6% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-01
Q2 2017 -$4.22B -$5.74B -$6.1B -1690% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-02
Q1 2017 $1.88B $895M -$270M -23.2% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-03
Q4 2016 $2.15B -$137M -$1.07B -115% Oct 1, 2016 Dec 31, 2016 10-K 2018-02-12
Q3 2016 $3.22B $765M -$245M -24.3% Jul 1, 2016 Sep 30, 2016 6-K 2017-11-02
Q2 2016 $3.47B $361M -$301M -45.5% Apr 1, 2016 Jun 30, 2016 6-K 2017-08-03
Q1 2016 $3.77B $1.17B +$416M +55.5% Jan 1, 2016 Mar 31, 2016 6-K 2017-05-11
Q4 2015 $3.35B $931M -$11M -1.17% Oct 1, 2015 Dec 31, 2015 10-K 2018-02-12
Q3 2015 $3.36B $1.01B -$102M -9.17% Jul 1, 2015 Sep 30, 2015 6-K 2016-11-15
Q2 2015 $3.47B $662M -$263M -28.4% Apr 1, 2015 Jun 30, 2015 6-K 2016-08-04
Q1 2015 $3.73B $749M -$223M -22.9% Jan 1, 2015 Mar 31, 2015 6-K 2016-05-09
Q4 2014 $3.95B $942M +$382M +68.2% Oct 1, 2014 Dec 31, 2014 20-F 2017-02-15
Q3 2014 $3.57B $1.11B +$311M +38.8% Jul 1, 2014 Sep 30, 2014 6-K 2015-10-29
Q2 2014 $3.26B $925M +$1.51B Apr 1, 2014 Jun 30, 2014 6-K 2015-07-30
Q1 2014 $1.75B $972M +$98M +11.2% Jan 1, 2014 Mar 31, 2014 6-K 2015-04-30
Q4 2013 $1.65B $560M +$230M +69.7% Oct 1, 2013 Dec 31, 2013 20-F 2016-02-11
Q3 2013 $1.42B $801M +$861M Jul 1, 2013 Sep 30, 2013 6-K 2014-10-30
Q2 2013 $558M -$586M -$1.59B -158% Apr 1, 2013 Jun 30, 2013 6-K 2014-07-31
Q1 2013 $2.15B $874M -$54M -5.82% Jan 1, 2013 Mar 31, 2013 6-K 2014-05-02
Q4 2012 $2.21B $330M -$280M -45.9% Oct 1, 2012 Dec 31, 2012 20-F 2015-02-09
Q3 2012 $2.49B -$60M -$1.1B -106% Jul 1, 2012 Sep 30, 2012 6-K 2013-10-31
Q2 2012 $3.58B $1.01B +$410M +68.7% Apr 1, 2012 Jun 30, 2012 6-K 2013-08-01
Q1 2012 $3.17B $928M +$61M +7.04% Jan 1, 2012 Mar 31, 2012 6-K 2013-05-02
Q4 2011 $3.11B $610M -$164M -21.2% Oct 1, 2011 Dec 31, 2011 20-F 2014-02-10
Q3 2011 $3.27B $1.04B -$153M -12.9% Jul 1, 2011 Sep 30, 2011 6-K 2012-11-01
Q2 2011 $3.43B $597M -$478M -44.5% Apr 1, 2011 Jun 30, 2011 6-K 2012-08-02
Q1 2011 $3.9B $867M +$33M +3.96% Jan 1, 2011 Mar 31, 2011 6-K 2012-05-09
Q4 2010 $3.87B $774M Oct 1, 2010 Dec 31, 2010 20-F 2013-02-12
Q3 2010 $1.19B Jul 1, 2010 Sep 30, 2010 6-K 2011-11-02
Q2 2010 $1.08B Apr 1, 2010 Jun 30, 2010 6-K 2011-07-28
Q1 2010 $834M Jan 1, 2010 Mar 31, 2010 6-K 2011-05-11
* An asterisk sign (*) next to the value indicates that the value is likely invalid.